IYH - iShares US Healthcare ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
194.41
+0.79 (+0.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close193.62
Open193.55
Bid0.00 x 1000
Ask0.00 x 900
Day's Range193.16 - 194.89
52 Week Range163.39 - 194.89
Volume49,992
Avg. Volume55,534
Net Assets2.09B
NAV189.62
PE Ratio (TTM)N/A
Yield1.08%
YTD Return9.51%
Beta (3y)1.02
Expense Ratio (net)0.43%
Inception Date2000-06-12
Trade prices are not sourced from all markets
  • ETF Trendslast month

    Health Care ETFs Respond Positively to Jobs Report

    The latest June jobs report published by the Bureau of Labor Statistics showed an increase of 215,000 jobs--9.2 percent higher than original forecasts--with health services being one of the top beneficiaries of the increase. The jobs report revealed that the education and health services sector represented the biggest net job gainer for June--54,000 new positions created. Of that number, about 25,000 came as a result of hiring in the health care sector.

  • How Incyte’s Jakafi Performed in Q1 2018
    Market Realist3 months ago

    How Incyte’s Jakafi Performed in Q1 2018

    Incyte’s (INCY) oncology drug Jakafi (ruxolitinib) is approved for the treatment of myelofibrosis and polycythemia vera, two rare types of blood cancer.

  • Allergan’s International Business in 1Q18
    Market Realist3 months ago

    Allergan’s International Business in 1Q18

    Allergan’s (AGN) International business includes the revenues from both specialized therapeutics portfolio and general products portfolio from outside the US markets.

  • Eli Lilly’s Valuation after Its 1Q18 Earnings
    Market Realist4 months ago

    Eli Lilly’s Valuation after Its 1Q18 Earnings

    Eli Lilly (LLY) surpassed Wall Street analysts’ estimates for EPS (earnings per share) and revenues in 1Q18. Reported EPS was $1.34 on revenues of $5.7 billion, compared to the estimate for EPS of $1.14 on revenues of $5.5 billion.

  • How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?
    Market Realist4 months ago

    How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?

    Johnson & Johnson’s (JNJ) consumer business includes various beauty products, baby care products, oral care products, over-the-counter products, women’s health products, and wound care products. The company’s consumer business reported 5.3% growth in revenues to $3.4 billion during 1Q18 as compared to $3.2 billion during 1Q17. The above chart compares the revenues of the various franchises in the consumer segment business since 1Q17.

  • Johnson & Johnson’s Revenue Estimates for 1Q18
    Market Realist4 months ago

    Johnson & Johnson’s Revenue Estimates for 1Q18

    As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17. Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment. The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor.

  • Key Updates on Akcea Therapeutics’ Volanesorsen
    Market Realist5 months ago

    Key Updates on Akcea Therapeutics’ Volanesorsen

    How Ionis Pharmaceuticals Is Positioned in 2018

  • ETF Trends6 months ago

    Healthcare Dip Could be a Buying Opportunity

    The Health Care Select Sector SPDR (NYSEArca: XLV), the largest exchange traded fund dedicated to the S&P 500’s third-largest sector weight, tumbled last week, but some market observers believe the decline ...

  • Merck’s 4Q17 Estimates: Revenue Growth Expected
    Market Realist7 months ago

    Merck’s 4Q17 Estimates: Revenue Growth Expected

    Expectations for Merck’s 4Q17 Earnings on February 2

  • Merck & Co.’s Human Vaccines Business in 3Q17
    Market Realist7 months ago

    Merck & Co.’s Human Vaccines Business in 3Q17

    Who’s Watching Merck & Co. in January 2018?

  • Johnson & Johnson’s 4Q17 Earnings on January 23: What to Expect
    Market Realist7 months ago

    Johnson & Johnson’s 4Q17 Earnings on January 23: What to Expect

    Johnson & Johnson’s 4Q17 Earnings on January 23: What to ExpectA look at Johnson & Johnson’s estimates

  • Developments for Ionis Pharmaceuticals Post-3Q17
    Market Realist7 months ago

    Developments for Ionis Pharmaceuticals Post-3Q17

    What's the Word on Ionis Pharmaceuticals This January?

  • How’s Incyte’s Valuation in January 2018?
    Market Realist7 months ago

    How’s Incyte’s Valuation in January 2018?

    New Insights for Incyte Corporation as of JanuaryA look at Incyte

  • Market Realist8 months ago

    How the US Economy Performed in 2017

    This year has been a year to watch the US economy. Hopes for change, tax reform, and industry-friendly policies drove the markets (SPY) higher.

  • Market Realist8 months ago

    How the Medical Expense Tax Deduction Affects the Healthcare Industry

    According to AARP, around 75% the population claiming these medical expense deductions from their income are 50 years or older.

  • iShares U.S. Healthcare ETF (IYH) Hits New 52-Week High
    Zacks10 months ago

    iShares U.S. Healthcare ETF (IYH) Hits New 52-Week High

    This healthcare ETF hits a new 52-week high. Are more gains in store for this ETF?

  • Benzinga11 months ago

    9 Million American Children Lost Funding For Their Insurance

    In 1928, Congress passed a joint resolution establishing Child Health Day, the express purpose of which was to raise awareness “of the fundamental necessity of a year-round program to protect and develop ...

  • Market Realist11 months ago

    Understanding Merck’s Valuation after 2Q17

    Merck reported EPS of $1.01 on revenues of ~$9.93 billion for 2Q17, compared with its EPS of $0.93 on revenues of $9.84 billion in 2Q16.

  • ETF Trends11 months ago

    A Positive Prognosis for Healthcare ETFs

    The Health Care Select Sector SPDR (NYSEArca: XLV ) , the largest healthcare exchange traded fund, is up nearly 3% over the past week as the second-best-performing sector in the S&P 500 this year continues ...

  • Market Realist11 months ago

    Eli Lilly’s Oncology Products in 2Q17

    Alimta's sales totaled $532.9 million during 2Q17, a 12.0% decrease compared to $607.1 million for 2Q16.

  • Market Realistlast year

    Bristol-Myers Squibb’s Virology Products in 2Q17

    Bristol-Myers Squibb’s (BMY) virology products portfolio includes products for the treatment of chronic virus infections.

  • ETF Trendslast year

    Checking Up With Healthcare ETFs

    The healthcare sector, the third-largest sector weight in the S&P 500, is one of the legitimate leadership groups in the U.S. this year. In fact, healthcare trails only technology in terms of year-to-date ...

  • Market Realistlast year

    Johnson & Johnson’s Revenue Continues to Grow in 2Q17

    Johnson & Johnson (JNJ) reported ~2% growth in its top line to $18.8 billion in 2Q17, compared with $18.5 billion in 2Q16. The company surpassed analysts’ EPS (earnings-per-share) estimate of of…

  • Market Realistlast year

    Incyte Had These Key Collaborations and Developments in 2Q17

    Incyte (INCY) distributes its key drug, Jakafi, through its own network of specialty pharmacy providers and wholesalers in US markets.

  • Market Realistlast year

    How Allergan’s Segments Contributed to Overall Revenues

    The US Specialized therapeutics business includes products from various therapeutic areas including eye care, medical aesthetics including skin care, facial aesthetics, plastic surgery and other products, ...